Search the Newsreel

Oncology Institute Inc (TOI) Earnings Forecast: Future EPS & Revenue Growth Estimates

Form 8K Oncology Institute Inc For: 6 August By Investing.com

The article reports on an 8K filing by Oncology Institute Inc. for August 6. It includes a stock market publication timestamp and references the company's stock symbol STLN. The content also features various market data, trending stocks, and related news headlines.

Oncology Institute (NASDAQ:TOI) Issues Quarterly Earnings Results, Misses Estimates By $0.01 EPS

The Oncology Institute, Inc. Revenue Breakdown – NASDAQ:STLN

The Oncology Institute, Inc. (NASDAQ: STLN) generated $502.73 million in revenue last year, with its Dispensary segment being the top performer, contributing $269.18 million. The majority of its revenue, $502.73 million, originated from the United States. This indicates a strong domestic market for the …

Cash per share of The Oncology Institute, Inc. – NASDAQ:STLN

This article focuses solely on "Cash per share of The Oncology Institute, Inc. – NASDAQ:STLN". It provides the stock symbol STLN, identifies it as being listed on the Nasdaq Stock Market, and categorizes the company under Health Services / Medical/Nursing Services. The content is …

The Oncology Institute, Inc. will Change its Ticker to STLN from TOI

The Oncology Institute, Inc. announced that its stock ticker symbol on the Nasdaq Capital Market will change from TOI to STLN, effective August 4, 2026. This change follows the company's recent name change to Starling Oncology, Inc.

The Oncology Institute Changes Name to Starling Oncology

The Oncology Institute, Inc. has officially changed its name to Starling Oncology, Inc. The company, which manages community-based oncology practices across 86 clinic locations in five states, continues to provide medical oncology services, including physician services, infusion, radiation, and clinical trials. This name change …

The Oncology Institute Rebrands as Starling Oncology

The Oncology Institute (TOI), a major value-based oncology group in the U.S., has officially rebranded as Starling Oncology, Inc. The company's stock will now trade on Nasdaq under the new ticker symbol "STLN" starting August 4, 2026. This rebrand signifies the company's growth and …

Price to sales forward of The Oncology Institute, Inc. – NASDAQ:TOIIW

This article provides financial information for The Oncology Institute, Inc. (NASDAQ:TOIIW) focusing on its price to sales forward metric. It appears to be a financial data page from TradingView, displaying market data, financial figures, and general company information for the stock.

Enterprise value to EBITDA forward of The Oncology Institute, Inc. – NASDAQ:TOIIW

The article provides financial information for The Oncology Institute, Inc. (NASDAQ: TOIIW), focusing on its enterprise value to EBITDA forward. It is presented within the TradingView platform, detailing financial metrics and market data related to the company.

Price to earnings forward of The Oncology Institute, Inc. – NASDAQ:TOIIW

The article presents financial information for The Oncology Institute, Inc. (NASDAQ: TOIIW), specifically focusing on its price-to-earnings forward metric. It appears to be a stub or a section of a larger financial data platform, providing a snapshot of the company's financial overview without detailed …

Form 4 Oncology Institute Inc For: 29 July By Investing.com

This article announces the filing of Form 4 for Oncology Institute Inc. on July 29. It appears to be a standard financial news brief from Investing.com, providing basic information about the regulatory filing. The content itself is minimal, serving primarily as a notification rather …

Oncology Institute (TOI) grants 29,116 RSUs to company director

Oncology Institute (TOI) director Kimberly Jo Tzoumakas was granted 29,116 restricted stock units (RSUs) on July 27, 2026. These RSUs, which vest fully at the company's 2027 annual meeting of stockholders, increase her direct holdings to 46,301 shares. The grant is a form of …

Oncology Institute, Inc. (TOI) awards 33,133 RSUs to director Kaushal Mohit

Oncology Institute, Inc. (TOI) director Kaushal Mohit was granted 33,133 restricted stock units (RSUs) on July 27, 2026, as reported in a Form 4 filing. These RSUs will vest in full at the company’s 2027 annual meeting of stockholders, provided Mohit continues his service. …

TOI|Oncology Institute Inc|Price:4.755|Chg%:-0.195

This article provides a comprehensive stock analysis of Oncology Institute Inc (TOI), highlighting its strong fundamentals, high growth potential, and fair valuation within the Healthcare Providers & Services industry. It notes a high institutional ownership and a positive outlook from analysts, with a highest …

The Oncology Institute, Inc. Revenue Breakdown – NASDAQ:TOIIW

The Oncology Institute, Inc. (NASDAQ: TOIIW) generated $502.73 million USD in revenue last year. Its top-performing segment was Dispensary, contributing $269.18 million USD, a significant increase from $179.92 million USD the previous year. The United States was the primary geographic contributor, accounting for all …

Oncology Institute (TOI) to Release Quarterly Earnings on Thursday

Oncology Institute Inc (TOI) Institutional Confidence

The Oncology Institute Inc (TOI) has an institutional shareholding score of 3.00, placing it 55th out of 75 in its industry. The institutional shareholding proportion has increased by 17.31% quarter-over-quarter to 47.57%. Key institutional shareholders and their recent activity are listed, such as Chernett …

Oncology Institute, Inc. (TOI) awards 31,124 RSUs to board director

Oncology Institute, Inc. (TOI) director Mark Stolper has been granted 31,124 restricted stock units (RSUs) as equity compensation. These RSUs, granted at $0.00 per share, vest in full on the date of the company's 2027 annual meeting of stockholders, provided Stolper continues his service. …

Oncology Institute, Inc. (TOI) grants RSU equity award to director

Oncology Institute, Inc. (TOI) director Anne McGeorge received a grant of 41,165 restricted stock units (RSUs). These RSUs vest in full on the date of the company's 2027 annual meeting of stockholders, contingent on her continued service. Following this award, her direct holdings in …

Oncology Institute (NASDAQ: TOI) awards 30,120 RSUs to director

Oncology Institute director Mark L. Pacala was granted 30,120 restricted stock units (RSUs), increasing his direct holdings to 286,881 shares. These RSUs will vest in full at the company's 2027 annual meeting of stockholders, contingent upon his continued service. This transaction was reported in …

Oncology Institute Inc (TOI) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Oncology Institute Inc (TOI), noting its current valuation score of 7.50, ranking 52 out of 75 in its industry. The company's current P/E ratio is -13.88, which is significantly below its recent high and above its recent …

Insider Buying: Oncology Institute (NASDAQ:TOI) Major Shareholder Buys 18,000 Shares

The Oncology Institute Announces Second Quarter 2026 Earnings Release Date and Conference Call

The Oncology Institute, Inc. (TOI) announced that it will release its second quarter 2026 financial results on Thursday, August 6, 2026. This will be followed by a conference call at 5:00 p.m. (Eastern Time) on the same day. Interested parties can access the call …

The Oncology Institute's Q2 results call will stream online Aug. 6

The Oncology Institute (NASDAQ: TOI) announced it will release its second-quarter 2026 financial results on Thursday, August 6, 2026. A conference call will follow on the same day at 5:00 p.m. Eastern Time, accessible via dial-in numbers or a live webcast on the company’s …

Oncology Institute Inc (TOI) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Oncology Institute Inc (TOI), listing major individual and institutional holders and their respective proportions. It also provides a breakdown of shareholder types, institutional shareholding over several quarters, and recent shareholder activity, alongside related ETF holdings. Key insights …

Oncology Institute Inc (TOI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Oncology Institute Inc (TOI), detailing its business segments for FY2025. Key revenue streams include Dispensary revenue, FFS revenue, Capitated revenue, and Clinical research trials and other revenue, with dispensary revenue forming the largest proportion. The data presented …

TOI|Oncology Institute Inc|Price:4.980|Chg%:-0.090

Oncology Institute Inc (TOI) is trading at $4.980, down 1.78%, with a high growth potential and stable fundamentals. Analysts maintain a "Buy" rating with a target price of $8.40, suggesting a significant upside. Despite institutional selling in the last quarter, the company's revenue has …

Oncology Institute, Inc. (TOI) 10% owner adds 18,000 shares in open-market buy

Oncology Institute, Inc. (TOI) 10% owner Jorey Chernett purchased 18,000 shares of common stock on July 21, 2026, at a weighted average price of $5.27 per share. This transaction increases Chernett's direct ownership to 10,648,858 shares. The purchase was made in open-market or private …

Oncology Institute CMO Yale Podnos disposes of 23,452 common shares worth $150,362.95

Oncology Institute's Chief Medical Officer, Yale Podnos, exercised stock options on July 14, 2026, acquiring 23,452 common shares at $1.87 and $2. The same day, Podnos sold these 23,452 shares for $6.43 and $6.35, resulting in a decrease of his direct common share holdings …

BTIG Maintains The Oncology Institute(TOI.US) With Buy Rating, Maintains Target Price $9

BTIG has reiterated its Buy rating for The Oncology Institute (TOI.US), keeping its price target at $9. This indicates a continued positive outlook from the firm regarding the company's stock performance.

Form 4 Oncology Institute Inc For: 16 July By Investing.com

This article announces that Oncology Institute Inc. filed a Form 4 for insider transactions on July 16, as reported by Investing.com. The brief piece includes the stock symbol TOI, which experienced a -7.07% change. It provides minimal details beyond the filing announcement.

Oncology Institute, Inc. (TOI) CMO sells 23,452 shares after option exercises

Oncology Institute, Inc. Chief Medical Officer Yale Podnos sold a total of 23,452 common shares on July 14, 2026, after exercising stock options. The shares were sold at prices ranging from $6.35 to $6.429 under a pre-arranged Rule 10(b)5-1 trading plan. Following these transactions, …